Varex Imaging Corp. (VREX) - Q2 2025 Filing Summary
Business Context and Reporting Period
This summary covers the Form 10-Q for Varex Imaging Corporation for the quarterly period ended April 4, 2025, and the six-month period ended on the same date. Varex designs, manufactures, and sells X-ray imaging components for medical diagnostic, radiation therapy, dental, veterinary, and industrial security/inspection applications. The company operates through two segments: Medical and Industrial.
Key Financial Metrics
| Metric (in millions) | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenues, Net | $212.9 | $206.2 | $412.7 | $396.2 |
| Gross Profit | $76.7 | $65.8 | $145.2 | $122.9 |
| Gross Margin | 36.0% | 31.9% | 35.2% | 31.0% |
| Operating Income | $22.1 | $7.7 | $33.3 | $11.9 |
| Net Income (Varex) | $6.9 | $1.4 | $6.6 | $0.9 |
| Diluted EPS | $0.17 | $0.03 | $0.16 | $0.02 |
| Cash & Equivalents | $205.1 | $168.7 | $205.1 | $152.6 |
| Restricted Cash | $127.1 | $1.7 | $127.1 | $1.4 |
| Total Debt (Net) | $567.2 | $443.4 | $567.2 | $443.4 |
| Operating Cash Flow (YTD) | $26.1 | $13.4 | $26.1 | $13.4 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 3.2% QoQ and 4.2% YTD, driven by the Medical segment (+3.4% QoQ) due to higher sales in CT and oncology modalities. The Industrial segment grew 3.0% QoQ.
- Margin Expansion: Gross margin improved significantly to 36.0% (Q2 2025) from 31.9% (Q2 2024), attributed to improved productivity, lower material costs, and favorable product mix.
- Profitability Surge: Operating income more than doubled to $22.1 million from $7.7 million year-over-year, resulting in a net income increase to $6.9 million from $1.4 million.
- Debt Structure: Total debt increased by $123.8 million to $567.2 million. This reflects the issuance of $125.0 million in Senior Secured Notes in December 2024. Proceeds are held in restricted cash ($127.1 million) to repay $200.0 million in Convertible Notes maturing in June 2025.
- Interest Expense: Interest expense rose to $10.2 million (Q2 2025) from $7.9 million (Q2 2024) due to the new Senior Secured Notes and Revolving Credit Facility.
Guidance, Outlook, Risks, and Contingencies
- Debt Maturity: The company anticipates repaying the $200 million Convertible Notes due June 1, 2025, using restricted cash proceeds from the Senior Secured Notes Add-On and available revolver capacity.
- Trade War Impact: Significant risk exists regarding escalating tariffs between the U.S. and China. As of April 2025, U.S. tariffs on Chinese imports reached at least 145%, with China retaliating at 125%. Sales to China represented ~15% of fiscal 2024 revenue. Management is pursuing mitigation strategies but notes potential material adverse impacts.
- MOFCOM Investigations: China's Ministry of Commerce initiated investigations into imported X-ray tubes and CT tube inserts. Resolution is expected to take approximately one year, creating uncertainty for ~10% of total revenue.
- Goodwill Impairment Risk: Management performed a qualitative assessment and found no impairment trigger as of April 4, 2025. However, they noted that macroeconomic challenges, tariffs, and stock price declines increase the risk of future impairment if fair value falls below carrying value.
- Backlog: Estimated total backlog was approximately $316 million as of April 4, 2025.
Investor Verification Checklist
- Convertible Note Repayment: Verify the execution of the repayment plan for the $200 million Convertible Notes maturing in June 2025 and the utilization of the $127.1 million in restricted cash.
- Tariff Mitigation: Assess the effectiveness of management's strategies to offset the impact of 145%+ U.S. tariffs on Chinese imports and 125% Chinese retaliatory tariffs.
- MOFCOM Outcome: Monitor the progress of the Chinese government investigations into X-ray tubes, which could affect pricing competitiveness and market access in China.
- Customer Concentration: Note that one customer (Canon Medical Systems) accounted for 19.0% of Q2 revenue and 14.8% of accounts receivable.
- Debt Covenants: Review compliance with the Revolving Credit Facility's consolidated total net leverage ratio (max 4.25:1.00 through Q2 2025) and fixed charge coverage ratio.